What this is
- How it works
- How it works isn't classified yet
- Tested for
- Alopecia Areata
- Main trialPhase 2
- “The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).”In the company’s words, NCT06104839 on ClinicalTrials.gov
Other drugs for Alopecia Areata
- RitlecitinibPfizer · Phase 3
- DeuruxolitinibSun Pharma · Phase 3
- UpadacitinibAbbVie · Phase 3
- ALD-102Aldena Therapeutics · Phase 1/2
- SYHX1901CSPC · Phase 2
- LAD603Almirall, S.A. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Oct 2026 | Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata | |
| Phase 1Completed | 1 Nov 2022 | A First-in-Human Study to Assess Single and Multiple Doses of NXC736 in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026